A-804598
A-804598 is a potent and selective antagonist of the P2X7 receptor, a type of purinergic receptor that is activated by adenosine triphosphate (ATP). The P2X7 receptor is a ligand-gated ion channel that plays a significant role in the immune system, particularly in the process of inflammation and cell death.
Mechanism of Action[edit | edit source]
A-804598 functions by inhibiting the P2X7 receptor, which is known to mediate the release of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α). By blocking this receptor, A-804598 can reduce inflammation and has potential therapeutic applications in diseases characterized by excessive inflammatory responses.
Pharmacological Properties[edit | edit source]
A-804598 is characterized by its high selectivity for the P2X7 receptor over other P2X receptor subtypes. This selectivity is crucial for minimizing off-target effects and enhancing the therapeutic potential of the compound. The pharmacokinetics of A-804598, including its absorption, distribution, metabolism, and excretion, are subjects of ongoing research.
Therapeutic Potential[edit | edit source]
The inhibition of the P2X7 receptor by A-804598 has been explored in various preclinical models of inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and neurodegenerative disorders such as Alzheimer's disease. The compound's ability to modulate immune responses makes it a promising candidate for the development of new anti-inflammatory therapies.
Research and Development[edit | edit source]
A-804598 is primarily used in research settings to study the role of the P2X7 receptor in health and disease. Its development as a therapeutic agent is still in the experimental stages, with ongoing studies aimed at understanding its efficacy and safety profile in various disease models.
Safety and Toxicology[edit | edit source]
As with any investigational compound, the safety and toxicological profile of A-804598 is critical. Preclinical studies are necessary to evaluate potential adverse effects and to establish safe dosage ranges for future clinical trials.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
